Crizotinib was the first ALK inhibitor to undergo clinical assessment and showed encouraging results in early trials for EML4-ALK-positive NSCLC (NCT00585195; NCT00932451) [107,108,109]. The gene discussed is ALK; the disease is non-small cell lung carcinoma.